Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

Blood (2023) 142 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2023-180141

Published: 2023

Journal Articles

Optical Genome Mapping Allows Detection and Characterization of Cytogenetically Cryptic Oncogenic Fusions in Pediatric Acute Myeloid Leukemia

Gordana Raca, Alexandra E. Kovach, Karin Miller, Jennifer Han, Katherine Ma, Cindy Fong, Jianling Ji, Ryan Schmidt, Andrew Doan, Deepa Bhojwani

Blood (2023) 142 (Supplement 1): 5038.

https://doi.org/10.1182/blood-2023-188356

Published: 2023

Journal Articles

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)

Armin Ghobadi, Ibrahim Aldoss, Shannon L. Maude, Deepa Bhojwani, Alan S. Wayne, Ashish Bajel, Rawan Faramand, Ryan J Mattison, Bhagirathbhai Dholaria, Michael P. Rettig, Ken Jacobs, Ouiam Bakkacha, John Muth, Angela Pannunzio, Brett Ramsey, Eileen McNulty, Matt L. Cooper, Jan Davidson-Moncada, John F. DiPersio

Blood (2023) 142 (Supplement 1): 770.

https://doi.org/10.1182/blood-2023-178723

Published: 2023

Journal Articles

Risk Stratified Treatment for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase 1/2 Non-Randomized Study of Trametinib and Azacitidine with or without Chemotherapy

Elliot Stieglitz, Yueh-Yun Chi, Bill H. Chang, Sarah K. Tasian, Marielle Yohe, Christopher C Dvorak, Erica Southworth, Janel R. Long-Boyle, Jessica Van Ziffle, Zied Abdullaev, Roy Leong, Alan S. Wayne, Deepa Bhojwani, Mignon L. Loh

Blood (2023) 142 (Supplement 1): 3210.

https://doi.org/10.1182/blood-2023-177838

Published: 2023

Journal Articles

Impact of Central Nervous System (CNS) Leukemia Status-Based Therapeutic Protocol Change on the Incidence of CNS2 Diagnosis in Pediatric B-Lymphoblastic Acute Leukemia

Alyssa Rodriguez, Maximilian Wengyn, My H. Vu, Andrew Doan, Gordana Raca, Deepa Bhojwani, Paul S. Gaynon, Alexandra E. Kovach

Blood (2023) 142 (Supplement 1): 1457.

https://doi.org/10.1182/blood-2023-190743

Published: 2023

Journal Articles

Impact of Treatment with Inotuzumab Ozogamicin before or after Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Lymphoblastic Leukemia

Susan R Rheingold, Lingyun Ji, Lia Gore, Xinxin Xu, Deepa Bhojwani, Nirali N. Shah, Elizabeth A. Raetz, Mignon L. Loh, Maureen M. O'Brien

Blood (2023) 142 (Supplement 1): 2876.

https://doi.org/10.1182/blood-2023-183103

Published: 2023

Journal Articles

Results from the Phase 1 Portion of a Trial of Oral Ixazomib Combined with Chemotherapy in Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoma in Children, Adolescents and Young Adults: A Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Eric S. Schafer, Yueh-Yun Chi, Jemily Malvar, Teresa Rushing, Andrew Doan, Holly L. Pacenta, Reuven J. Schore, Richard Sposto, Roy Leong, Paul S. Gaynon, Jeffrey E. Rubnitz, Julio C. Barredo, Tamra Slone, Melinda Pauly, Alan S. Wayne, Deepa Bhojwani, Terzah M. Horton

Blood (2023) 142 (Supplement 1): 2872.

https://doi.org/10.1182/blood-2023-180414

Published: 2023

Journal Articles

The Role of Integrin Beta-1 in the Chemoresistance of Acute Myeloid Leukemia

Heather Ogana, Samantha Hurwitz, Zesheng Wan, Hye Na Kim, Samy Jambon, Hisham Abdel-Azim, Miller Huang, Moghimi Babak, Nora Heisterkamp, Anne-Marie Carbonell, Chintan Parekh, Marina Konopleva, Deepa Bhojwani, Yong-Mi Kim

Blood (2022) 140 (Supplement 1): 8799–8800.

https://doi.org/10.1182/blood-2022-167902

Published: 2022

Journal Articles

TBL1 Inhibitor, Tegavivint, Supresses Cell Survival and Promotes Sensitivity to Chemotherapy in ALL and AML

Samantha Hurwitz, Heather Ogana, Zesheng Wan, Fariba Navid, Deepa Bhojwani, Yong-Mi Kim

Blood (2022) 140 (Supplement 1): 5995.

https://doi.org/10.1182/blood-2022-167445

Published: 2022

Journal Articles

Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML

Blood (2022) 140 (Supplement 1): 159–161.

https://doi.org/10.1182/blood-2022-162842

Published: 2022

Journal Articles

Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype

Henrik Hasle, Ronald M. Kline, Eigil Kjeldsen, Nik F. Nik-Abdul-Rashid, Deepa Bhojwani, Jeffrey M. Verboon, Stephanie P. DiTroia, Katherine R. Chao, Klas Raaschou-Jensen, Josefine Palle, C. Michel Zwaan, Charlotte Guldborg Nyvold, Vijay G. Sankaran, Alan B. Cantor

Blood (2022) 139 (21): 3159–3165.

https://doi.org/10.1182/blood.2021011463

Published: 2022

Includes: Supplemental data

Journal Articles

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL)

Armin Ghobadi, Ibrahim Aldoss, Frederick L. Locke, Ryan J. Mattison, Deepa Bhojwani, Shannon L. Maude, Preeta Dasgupta, Karen Gheesling Mullis, Ayman Kabakibi, Alexander S. Hamil, Tom Leedom, Kenneth Chrobak, Eileen McNulty, Jan K Davidson-Moncada, Matthew L Cooper, John F. DiPersio

Blood (2021) 138 (Supplement 1): 4829.

https://doi.org/10.1182/blood-2021-146841

Published: 2021

Journal Articles

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732

Jennifer L. McNeer, Maureen M. O'Brien, Susan R. Rheingold, Meenakshi Devidas, Zhiguo Chen, Deepa Bhojwani, Anurag K. Agrawal, Brent Wood, Eugene Suh, Sarah Alexander, Tamara P. Miller, Olga Militano, Elizabeth A. Raetz, Mignon L. Loh

Blood (2021) 138 (Supplement 1): 3398.

https://doi.org/10.1182/blood-2021-149478

Published: 2021

Journal Articles

Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) in Combination with UK ALL-R3 Induction Chemotherapy for Children, Adolescents and Young Adults with Relapsed Acute Lymphoblastic Leukemia (ALL): A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Blood (2021) 138 (Supplement 1): 3402.

https://doi.org/10.1182/blood-2021-149365

Published: 2021

Journal Articles

Asparaginase Induced Liver Enzyme Elevation Is More Prevalent in Hispanics Children with ALL and in Patients with SOD2 rs4880 CC Genotype

Sharon Wu, Mengxi Wang, Amani Ali Alqahatni, Mimi Lou, Wendy Stock, Deepa Bhojwani, Houda Alachkar

Blood (2021) 138 (Supplement 1): 2279.

https://doi.org/10.1182/blood-2021-154268

Published: 2021

Journal Articles

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 256.

https://doi.org/10.1182/blood-2021-153336

Published: 2021

Journal Articles

Cortical Thinning and Neuropsychologic Measures Predict CD19 CAR T Cell Therapy-Associated Neurotoxicity

Agne Taraseviciute, MD, Deepa Bhojwani, MD, Ravi Bansal, PhD, Bradley S Peterson, MD, Michael A Pulsipher, MD, Alan S. Wayne, MD, Courtney Allem, Michael Sheard, PhD, Joey Trampush, PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-142609

Published: 2020

Journal Articles

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

Agne Taraseviciute, MD, Seth M. Steinberg, PhD, Regina M. Myers, MD, Lia Gore, MD, Adam J. Lamble, MD, Patrick A. Brown, MD, Jennifer Sheppard, Bonnie Yates, NP, Perry Chung, MD, Lee Chen, Colleen Annesley, MD, Deepa Bhojwani, MD, Theodore W. Laetsch, MD, Rebecca A Gardner, MD, Susan R. Rheingold, MD, Michael A Pulsipher, MD, Nirali N. Shah, MD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139260

Published: 2020

Journal Articles

Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia

Blood (2020) 136 (2): 210–223.

https://doi.org/10.1182/blood.2019001417

Published: 2020

Includes: Supplemental data

Journal Articles

Immunologic and Brain Bases of Neurotoxicity Associated with CAR T-Cell Therapy

Deepa Bhojwani, MD, Bradley Peterson, MD, Agne Taraseviciute, MD PhD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Michael Sheard, PhD, Courtney Allem, Joey Trampush, PhD, Ravi Bansal, PhD

Blood (2019) 134 (Supplement_1): 1946.

https://doi.org/10.1182/blood-2019-127533

Published: 2019

NARROW

Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

Optical Genome Mapping Allows Detection and Characterization of Cytogenetically Cryptic Oncogenic Fusions in Pediatric Acute Myeloid Leukemia

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)

Risk Stratified Treatment for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase 1/2 Non-Randomized Study of Trametinib and Azacitidine with or without Chemotherapy

Impact of Central Nervous System (CNS) Leukemia Status-Based Therapeutic Protocol Change on the Incidence of CNS2 Diagnosis in Pediatric B-Lymphoblastic Acute Leukemia

Impact of Treatment with Inotuzumab Ozogamicin before or after Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Lymphoblastic Leukemia

Results from the Phase 1 Portion of a Trial of Oral Ixazomib Combined with Chemotherapy in Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoma in Children, Adolescents and Young Adults: A Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

The Role of Integrin Beta-1 in the Chemoresistance of Acute Myeloid Leukemia

TBL1 Inhibitor, Tegavivint, Supresses Cell Survival and Promotes Sensitivity to Chemotherapy in ALL and AML

Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML

Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL)

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732

Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) in Combination with UK ALL-R3 Induction Chemotherapy for Children, Adolescents and Young Adults with Relapsed Acute Lymphoblastic Leukemia (ALL): A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Asparaginase Induced Liver Enzyme Elevation Is More Prevalent in Hispanics Children with ALL and in Patients with SOD2 rs4880 CC Genotype

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Cortical Thinning and Neuropsychologic Measures Predict CD19 CAR T Cell Therapy-Associated Neurotoxicity

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia

Immunologic and Brain Bases of Neurotoxicity Associated with CAR T-Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only